ABBVIE INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 156.9 EUR | +1.47% |
|
+2.24% | +12.69% |
| 03:21pm | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
| 03:17pm | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
| Sales 2024 * | 55.19B 50.61B | Sales 2025 * | 58.21B 53.38B | Capitalization | 300B 275B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.6B 7.89B | Net income 2025 * | 11.44B 10.49B | EV / Sales 2024 * | 6.4 x |
| Net Debt 2024 * | 53.45B 49.01B | Net Debt 2025 * | 44.6B 40.9B | EV / Sales 2025 * | 5.92 x |
| P/E ratio 2024 * |
29.1
x | P/E ratio 2025 * |
23.3
x | Employees | 50,000 |
| Yield 2024 * |
3.67% | Yield 2025 * |
3.83% | Free-Float | 96.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie Inc.
More recommendations
More press releases
More news
| 1 day | +1.48% | ||
| 1 week | +2.24% | ||
| Current month | -1.35% | ||
| 1 month | +2.44% | ||
| 3 months | +2.97% | ||
| 6 months | +5.20% | ||
| Current year | +12.69% |
1 week
153.28
156.86
1 month
150.82162.20
Current year
141.40168.80
1 year
119.00168.80
3 years
89.89168.80
5 years
56.00168.80
10 years
37.79168.80
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 53 | 11-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Richard Gonzalez
CHM | Chairman | 70 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
| Director/Board Member | 70 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-12 | 156.9 | +1.47% | 32 |
| 24-07-11 | 154.6 | -0.26% | 402 |
| 24-07-10 | 155 | +0.44% | 54 |
| 24-07-09 | 154.3 | +0.42% | 65 |
| 24-07-08 | 153.7 | +0.16% | 29 |
Delayed Quote Deutsche Boerse AG, July 12, 2024 at 06:22 am EDT
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
2024-07-14
- Détachement de
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
169.9
USD
Average target price
183.3
USD
Spread / Average Target
+7.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +62.61% | 841B | |
| +40.42% | 625B | |
| -4.04% | 360B | |
| +17.47% | 327B | |
| +15.66% | 242B | |
| +17.90% | 227B | |
| +15.77% | 174B | |
| +0.90% | 162B | |
| +5.17% | 127B |
- Stock Market
- Equities
- ABBV Stock
- 4AB Stock
